Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 5/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.36 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.36 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.36 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1256596 | 0.98 | PTGS2 (0.47) | PTGS2TDP1ELANEPSMB5CASP3 | |
| SCHEMBL27847334 | 0.92 | PTGS2 (0.41) | PTGS2TDP1F2RL1PDE3BPDE3A | |
| SCHEMBL11815728 | 0.83 | PTGS2 (0.59) | PTGS2TDP1ELANEPSMB5F2RL1 | |
| SCHEMBL18951170 | 0.83 | PTGS2 (0.42) | PTGS2TDP1PSMB5CASP3SENP8 | |
| SCHEMBL29277524 | 0.81 | NISCH (0.38) | NPSR1MEN1KMT2ANISCH | |
| SCHEMBL4850917 | 0.77 | PTGS2 (0.46) | PTGS2TDP1ELANEPSMB5F2RL1 | |
| SCHEMBL4856447 | 0.77 | PTGS2 (0.46) | PTGS2TDP1ELANEPSMB5F2RL1 | |
| SCHEMBL10580729 | 0.77 | PTGS2 (0.46) | PTGS2TDP1ELANEPSMB5F2RL1 | |
| SCHEMBL4850921 | 0.77 | PTGS2 (0.46) | PTGS2TDP1ELANEPSMB5F2RL1 | |
| SCHEMBL28758944 | 0.77 | PTGS2 (0.51) | PTGS2TDP1ELANEPSMB5F2RL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822548-B2 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7825265-B2 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. (US) | 2010-11-02 | — | — | US | disclosed |
| EP-2233474-A1 | CONDENSED AMINODIHYDROTHIAZINE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| WO-2008033894-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2007056500-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ACADIA PHARMACEUTICALS INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1747182-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | Acadia Pharmaceuticals Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | ACADIA PHARMACEUTICALS INC. | 2006-06-08 | — | — | US | disclosed |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ACADIA PHARMACEUTICALS INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005108337-A2 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTOR | ACADIA PHARMACEUTICALS INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122278-A1 | di-aromatic compounds for treatment and prevention of diseases and disorders related to estrogen receptors; 2-fluoro-1-methoxy-4-(1-phenyl-cyclohexyl)-benzene | GPER1, ESR1, ESR2 | PTGS2 1709/4885TDP1 1590/4885ELANE 1816/4885 |
| US-20110046237-A1 | COMPOUNDS WITH ACTIVITY AT ESTROGEN RECEPTORS | ESR2, ESR1, GPER1 | PTGS2 1384/4885TDP1 2292/4885ELANE 826/4885 |
| US-20050256210-A1 | Compounds with activity at estrogen receptors | ESR2, GPER1, ESRRG | PTGS2 617/4885TDP1 2334/4885ELANE 982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.